Bristol Myers Squibb has voluntarily withdrawn FDA approval of Opdivo as a mototherapy for patients with hepatocellular carcinoma. The decision came after the FDA evaluated accelerated approval of inhibitors, including Opdivo, that failed to meet postmarketing requirements.